Pegcetacoplan
Phase 3Recruiting 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Delayed Graft Function
Conditions
Delayed Graft Function, End Stage Renal Disease, Deceased Donor Kidney Transplant
Trial Timeline
Feb 1, 2026 → Aug 1, 2028
NCT ID
NCT07020832About Pegcetacoplan
Pegcetacoplan is a phase 3 stage product being developed by Apellis Pharmaceuticals for Delayed Graft Function. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07020832. Target conditions include Delayed Graft Function, End Stage Renal Disease, Deceased Donor Kidney Transplant.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04729062 | Pre-clinical | Completed |
| NCT07020832 | Phase 3 | Recruiting |
| NCT06161584 | Pre-clinical | Active |
| NCT05809531 | Phase 3 | Active |
| NCT05067127 | Phase 3 | Completed |
| NCT04572854 | Phase 2 | Active |
| NCT04901936 | Phase 2 | Recruiting |
| NCT03531255 | Phase 3 | Active |
| NCT03593200 | Phase 2 | Completed |
| NCT03465709 | Phase 1/2 | Terminated |
| NCT02588833 | Phase 1 | Completed |
| NCT02503332 | Phase 2 | Completed |
| NCT02264639 | Phase 1 | Completed |
| NCT02461771 | Phase 1 | Completed |
Competing Products
8 competing products in Delayed Graft Function
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| azathioprine + sirolimus | Astellas Pharma | Approved | 85 |
| Lemborexant + Placebo | Eisai | Approved | 85 |
| Belatacept + Everolimus | Bristol Myers Squibb | Phase 1 | 32 |
| Belatacept + Calcineurin Inhibitor | Bristol Myers Squibb | Phase 2 | 51 |
| ARGX-117 | Argenx | Phase 2 | 49 |
| BG9418 (interferon beta-1a) | Biogen | Pre-clinical | 20 |
| Desflurane + Propofol | Baxter | Approved | 82 |
| TNX-2110 + TNX-2120 + TNX-2130 + CANDIN + Diluent | Tonix Pharmaceuticals | Phase 1 | 25 |